To predict symptom refractoriness and determine the underlying cause of refractory reflux-like symptoms (rRLS), which are defined as persistent symptoms despite treatment, using mid-esophageal mucosal impedance.
Key Findings:
Refractory reflux-like symptoms were prevalent in 20-46% of patients despite PPI therapy, indicating a need for alternative treatment approaches.
Mid-esophageal impedance measurements may reflect broader mucosal integrity and sensory phenotypes, suggesting their role in understanding symptom persistence.
Baseline impedance values can provide objective insights into mucosal integrity and inflammation, potentially guiding therapeutic decisions.
Interpretation:
Mid-esophageal mucosal impedance could serve as a valuable tool in assessing mucosal integrity and understanding the etiology of refractory reflux-like symptoms, potentially guiding treatment strategies and improving patient outcomes.
Limitations:
Retrospective design limits the ability to establish causality and may introduce bias.
Symptom assessment relied on self-reported data rather than validated measures, which could affect reliability.
Lack of objective verification for PPI adherence may impact the accuracy of findings.
Conclusion:
The study highlights the potential of mid-esophageal mucosal impedance as a diagnostic tool for patients with refractory reflux-like symptoms, warranting further investigation.
